Posted by Michael Wonder on 16 Jul 2018
NICE backs AZ’s asthma biologic Fasenra
16 July 2018 - AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
NICE has published draft guidelines recommending the drug as an option for treating the condition when standard therapies - including inhaled corticosteroids and beta-agonists - have failed.
Fasenra (benralizumab) was considered by NICE to be cost-effective for people who have had at least three exacerbations in the last year, a blood eosinophil count of 400 or more cells/mcL, and only when biological treatment mepolizumab is not appropriate.
